← ANALYST RATINGS · TIPRANKS
Eledon Pharmaceuticals (ELDN): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $8.00, the highest $8.00, the lowest $8.00. The average is +275.6% from the last price of $2.13.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Sell | −6.1% | Downgrade | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Sell | −6.1% | Downgrade | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Sell | −6.1% | Downgrade | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −6.1% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $10.00 | Buy | +369.5% | Reiterated | 23.09.26on TipRanks 09:10 | −5.2%next day −1.4% · 5 days −6.3% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $8.00 | Buy | +275.6% | Reiterated | 22.09.26on TipRanks 11:07 | +7.5%next day −5.2% · 5 days −12.3% | ↗ |
| Unknown Analyst | Guggenheim | $8.00 | Buy | +275.6% | Reiterated | 13.08.26on TipRanks Aug 14 10:55 | −2.6%next day −4.1% · 5 days −2.9% | ↗ |
| Seema Sheoran★★★★★★★★★★#8280 · hits 33% · avg +0.9% | Rodman & Renshaw | $12.00 | Buy | +463.4% | Initiated | 21.07.26on TipRanks Jul 27 13:58 | +1.5%next day −5.7% · 5 days −12.9% | ↗ |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | — | Buy | — | Reiterated | 23.01.26on TipRanks 09:40 | −4.1%next day +2.8% · 5 days +2.4% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $9.00 | Buy | +322.5% | Reiterated | 10.11.25on TipRanks 07:00 | +7.7%next day −5.6% · 5 days −25.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Eledon Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.50 at a price of $2.53 (+275.5%); now: $9.50 at $2.13 (+346.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 4 | 3 | 3 |
| Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.19 (from $-0.21 to $-0.15). Last quarter: $-0.27.
Best top-analyst consensus in the sector · Healthcare
About Eledon Pharmaceuticals
- CEO: David-Alexandre C. Gros
- Employees: 33
- 19900 MacArthur Boulevard, Irvine, CA, 92612, US
- eledon.com
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Data from the stock’s TipRanks forecast page, read 200 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗